Positive data from a pivotal phase II/III trial for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (QUILT 3032) and phase II trial in advanced pancreatic cancer (QUILT 88) were announced at the 2022 ASCO annual meeting.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease.
